The prestigious journal Nature Cancer has published preclinical results showing Pharmaxis’ pan-Lysyl Oxidase (pan-LOX) inhibitor PXS-5505 increases survival by 35% compared to chemotherapy treatment alone in the treatment of pancreatic ductal adenocarcinomas.
Research in mouse models, led by a team at the Garvan Institute of Medical Research also showed PXS-5505 combined with chemotherapy reduced the spread of the cancer to other organs such as the liver by 45%.
Read more here.